Icotinib hydrochloride, a molecular target drug for lung cancer that has attracted much attention, is a new generation of targeted anticancer drug by inhibiting EGFR kinases, and its first adaptation disease is advanced NSCLC(9). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.